Generic Name:
ripretinib
Project Status:
Active
Therapeutic Area:
Gastrointestinal stromal tumours
Manufacturer:
Medison Pharma Canada Inc.
Brand Name:
Qinlock
Project Line:
Reimbursement Review
Project Number:
PC0265-000
Tumour Type:
Gastrointestinal
NOC Status at Filing:
Post NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
Fee Schedule:
Schedule A
Indications:
For the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.